294 articles from MONDAY 2.11.2020
New simulation finds max cost for cost-effective health treatments
- ScienceDaily
- 20/11/2 23:32
As health care costs balloon in the U.S., experts say it may be important to analyze whether those costs translate into better population health. A new study analyzed existing data to find a dividing line - or ''threshold - for what makes a treatment cost-effective or not.
'Transparent solar cells' can take us towards a new era of personalized energy
- ScienceDaily
- 20/11/2 23:32
Solar power has shown immense potential as a futuristic, 'clean' source of energy. No wonder environmentalists worldwide have been looking for ways to advance the current solar cell technology. Now, scientists have put forth an innovative design for the development of a high-power transparent solar cell. This innovation brings us closer to realizing our goal of a sustainable green future with...
Two centuries of Monarch butterflies show evolution of wing length
- ScienceDaily
- 20/11/2 23:32
North America's beloved Monarch butterflies are known for their annual, multi-generation migrations in which individual insects can fly for thousands of miles. But Monarchs have also settled in some locations where their favorite food plants grow year round, so they no longer need to migrate. A new study of specimens collected over the last two centuries shows how wing length evolves in response...
COVID-19 'super-spreading' events play outsized role in overall disease transmission
- ScienceDaily
- 20/11/2 23:32
Researchers find COVID-19 super-spreading events, in which one person infects more than six other people, are much more frequent than anticipated, and that they have an outsized contribution to coronavirus transmission.
Rapid method finds potent COVID-19 monoclonal antibody among a trillion possibilities
- ScienceDaily
- 20/11/2 23:32
Scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. The method -- as well as a trio of successful animal studies on an antibody called 'Ab1' -- are described today in a new study. Ab1 is on track for human clinical trials by early next year.